



EPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Patent Examining Operations

Applicant(s): Ronald G. Lafreniere

Serial No: 10/534,419

Art Unit:

Filed: 12 November 2003

Examiner:

TITLE: HSAN II Related Gene and Expression Products and Uses Thereof

DOCKET: 760050-14517

1 May 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Applicant herewith submits the following:

1. Information Disclosure Statement (3 sheets);
2. Form 1449 (1 sheet) plus copies of 3 references; and
3. Self-addressed, Postage-paid Return Postcard.

The Commissioner is authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No: 10/534,419
Filed: 12 November 2003

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Alan J. Grant 5/1/06
Alan J. Grant, Esq. Date

Respectfully submitted,

Alan J. Grant

Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ronald G. Lafreniere

Serial No: 10/534,419 Art Unit:

Filed: 12 November 2003 Examiner:

TITLE: HSAN II Related Gene and Expression Products and Uses Thereof

DOCKET: 760050-14517

1 May 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449, which may be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

§1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.

Serial No: 10/534,419
Filed: 12 November 2003

No fee or statement is required.

 §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- The statement as specified in 37 CFR §1.97(e) set out below; OR
- The fee of \$180.00 under 37 CFR §1.17(p).

 §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND

is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

 §1.97(e) The undersigned Attorney hereby states that:

- each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

Serial No: 10/534,419
Filed: 12 November 2003

The Examiner is respectfully requested to consider and make of record all of the cited documents.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Alan J. Grant 5/1/06
Alan J. Grant, Esq. Date

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744



Form PTO-1449 INFORMATION DISCLOSURE STATEMENT				Atty. Docket: 760050-145		Serial No.: 10/534,419			
				Applicant: Ronald G. Lafreniere					
				Filing Date: 12 November 2003		Group:			
U.S. PATENT DOCUMENTS									
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date		
	A1								
	B1								
FOREIGN PATENT DOCUMENTS									
Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation		
	C1	WO 01/57187	9 August 2001	PCT					
	D1	WO 00/62798	26 October 2000	PCT					
	E1						<input type="checkbox"/> Yes <input type="checkbox"/> No		
	F1						<input type="checkbox"/> Yes <input type="checkbox"/> No		
	G1						<input type="checkbox"/> Yes <input type="checkbox"/> No		
	H1						<input type="checkbox"/> Yes <input type="checkbox"/> No		
	I1						<input type="checkbox"/> Yes <input type="checkbox"/> No		
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)									
	J1	GenBank Database, Muzny et al., 1 May 1999.							
	K1	Nicholson et al., The Gene for Hereditary Sensory Neuropathy Type I (HSN-I) Maps to Chromosome 9q22.1-822.3, Nature Genetics, Vol. 13, pp. 101-104 (1996)							
	L1	Samuels et al., Mutations in a Novel Gene Cause Hereditary Sensory and Autonomic Neuropathy Type II, Amer. J. Human Gen., Vol. 73, No. 5 (Abstract) 2003.							
	M1								
	N1								
	O1								
	P1								
	Q1								
	R1								
	S1								
Examiner:					Date Considered:				
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.									